InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report report published on Monday. The brokerage issued a sell rating on the stock.

Several other brokerages have also recently issued reports on NSPR. Lake Street Capital initiated coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price for the company. Piper Sandler restated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Up 0.4 %

NYSE NSPR opened at $2.68 on Monday. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42. The stock has a market capitalization of $69.91 million, a PE ratio of -3.57 and a beta of 0.99. The firm has a 50 day moving average of $2.78 and a two-hundred day moving average of $2.71.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The company had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the previous year, the business posted ($0.15) EPS. On average, equities research analysts expect that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD at the end of the most recent reporting period. 44.78% of the stock is owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.